Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chugai’s PNH Med, Takeda’s cTTP Therapy Up for Advisory Panel Review on Feb. 29
A key health ministry advisory panel will discuss on February 29 whether to endorse approval for a batch of new medicines including Chugai Pharmaceutical’s anti-C5 recycling monoclonal antibody crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Crovalimab is one…
To read the full story
Related Article
- Chugai’s PNH Med, Takeda’s cTTP Therapy Now in Line for Japan Approval
March 1, 2024
- Viatris Files Cystinosis Med in Japan
September 22, 2023
- Takeda Files cTTP Therapy ADAMTS-13 in Japan
August 18, 2023
- Meiji Seika Pharma Files GVHD Drug Belumosudil in Japan
June 28, 2023
- UCB Japan Seeks Lennox-Gastaut Syndrome Indication for Fintepla
June 28, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
REGULATORY
- Tavneos Slapped with Blue Letter in Japan over Liver Injury Risk
May 21, 2026
- MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
May 21, 2026
- Japan Approves Nonprescription Cialis, Rozerem
May 21, 2026
- MHLW Panel Clarifies Roles in Vaccine Policy Review Process
May 21, 2026
- Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…